Zimmer Biomet Holdings, Inc.

Valuation Analysis

About the Company

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of i

Zimmer Biomet Holdings, Inc. Stock at a Glance

Zimmer Biomet Holdings, Inc. (ZBH) is currently trading at $88.57 with a market capitalization of $17.1B. The trailing P/E ratio stands at 22.95x, with a forward P/E of 9.85x. The 52-week range spans from $79.12 to $108.29; the current price is 18.2% below the yearly high. Year-over-year revenue growth stands at +9.3%. The net profit margin stands at 9.05%.

💰 Dividend

Zimmer Biomet Holdings, Inc. pays an annual dividend of $0.96 per share, representing a yield of 1.08%. The payout ratio stands at 24.87%.

📊 Analyst Rating

20 analysts rate Zimmer Biomet Holdings, Inc. (ZBH) on consensus: Hold. The average price target is $98.70, implying +11.44% from the current price. Analyst price targets range from $83.00 to $130.00.

Zimmer Biomet Holdings, Inc.: The Investment Case in Detail

Zimmer Biomet Holdings, Inc. (ZBH) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Earnings growth of 34.1% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 70.18%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Valuation in Context

With a PEG ratio of 0.63, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 9.4x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

What to Watch Next

• The forward P/E of 9.85x is meaningfully below the trailing 22.95x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (5.92%).

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Zimmer Biomet Holdings, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.